GlassScriptPhysician profile
Tanya Watson
NPI 1134839707
$2,325.59
in general payments reported to CMS, 2019-2025
19 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $557 · 2024: $835 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $652.40 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $474.48 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $266.63 | 2024-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $207.88 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $125.23 | 2022 | |
| Glaxosmithkline, LLC. | $113.40 | 2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.67 | 2024-2025 | Jardiance, Jascayd |
| Dexcom, INC. | $59.05 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.38 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $55.06 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $49.54 | 2024-2025 | Kisunla, Zepbound, Mounjaro |
| Viatris Specialty LLC | $23.17 | 2025 | Yupelri |
| Mylan Specialty L.P. | $21.97 | 2023 | Yupelri |
| Lundbeck LLC | $21.62 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $21.08 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.72 | 2023 | Givlaari |
| Otsuka America Pharmaceutical, INC. | $16.90 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $16.31 | 2024 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $16.10 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.